1.42 USD
+0.04 (+2.9%)
1.4 USD
-0.02 (-1.41%)
LAB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. LAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LAB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
LAB had negative earnings in the past year.
LAB had a negative operating cash flow in the past year.
In the past 5 years LAB always reported negative net income.
In the past 5 years LAB always reported negative operating cash flow.
1.2 Ratios
LAB has a worse Return On Assets (-23.77%) than 70.69% of its industry peers.
Looking at the Return On Equity, with a value of -32.09%, LAB is doing worse than 62.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.77% | ||
| ROE | -32.09% | ||
| ROIC | N/A |
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LAB has a Gross Margin (47.94%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of LAB has declined.
LAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
2. Health
2.1 Basic Checks
LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
LAB has more shares outstanding than it did 1 year ago.
LAB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LAB has been reduced compared to a year ago.
2.2 Solvency
LAB has an Altman-Z score of -0.60. This is a bad value and indicates that LAB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.60, LAB is not doing good in the industry: 79.31% of the companies in the same industry are doing better.
LAB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
LAB has a Debt to Equity ratio of 0.00. This is in the better half of the industry: LAB outperforms 74.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.6 |
ROIC/WACCN/A
WACC10.19%
2.3 Liquidity
LAB has a Current Ratio of 4.38. This indicates that LAB is financially healthy and has no problem in meeting its short term obligations.
LAB's Current ratio of 4.38 is fine compared to the rest of the industry. LAB outperforms 67.24% of its industry peers.
A Quick Ratio of 4.14 indicates that LAB has no problem at all paying its short term obligations.
LAB has a better Quick ratio (4.14) than 74.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 4.14 |
3. Growth
3.1 Past
LAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.11%, which is quite impressive.
The Revenue for LAB has decreased by -17.37% in the past year. This is quite bad
LAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.28% yearly.
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)-17.37%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%-56.52%
3.2 Future
LAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.63% yearly.
LAB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -15.47% yearly.
EPS Next Y59.6%
EPS Next 2Y31.32%
EPS Next 3Y18.63%
EPS Next 5YN/A
Revenue Next Year-49.56%
Revenue Next 2Y-31.76%
Revenue Next 3Y-21.14%
Revenue Next 5Y-15.47%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LAB. In the last year negative earnings were reported.
Also next year LAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LAB's earnings are expected to grow with 18.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.32%
EPS Next 3Y18.63%
5. Dividend
5.1 Amount
LAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.42
+0.04 (+2.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners72.99%
Inst Owner ChangeN/A
Ins Owners2.54%
Ins Owner Change29.09%
Market Cap542.44M
Revenue(TTM)128.83M
Net Income(TTM)-128.25M
Analysts77.14
Price Target1.58 (11.27%)
Short Float %3.08%
Short Ratio7.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-36.7%
Min EPS beat(2)-62.02%
Max EPS beat(2)-11.39%
EPS beat(4)1
Avg EPS beat(4)-23.28%
Min EPS beat(4)-62.02%
Max EPS beat(4)7.59%
EPS beat(8)2
Avg EPS beat(8)-42.02%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.94%
Min Revenue beat(2)4.33%
Max Revenue beat(2)7.56%
Revenue beat(4)4
Avg Revenue beat(4)5.02%
Min Revenue beat(4)0.73%
Max Revenue beat(4)7.56%
Revenue beat(8)6
Avg Revenue beat(8)1.89%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.68%
PT rev (3m)-18.42%
EPS NQ rev (1m)-27.27%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)0%
EPS NY rev (3m)29.03%
Revenue NQ rev (1m)-4.53%
Revenue NQ rev (3m)-52.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-48.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.36 | ||
| P/tB | 1.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.34
BVpS1.05
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.77% | ||
| ROE | -32.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.94% | ||
| FCFM | N/A |
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
F-Score4
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 82.18% | ||
| Cap/Sales | 8.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 4.14 | ||
| Altman-Z | -0.6 |
F-Score4
WACC10.19%
ROIC/WACCN/A
Cap/Depr(3y)31.23%
Cap/Depr(5y)51.75%
Cap/Sales(3y)3.79%
Cap/Sales(5y)6.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y59.6%
EPS Next 2Y31.32%
EPS Next 3Y18.63%
EPS Next 5YN/A
Revenue 1Y (TTM)-17.37%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%-56.52%
Revenue Next Year-49.56%
Revenue Next 2Y-31.76%
Revenue Next 3Y-21.14%
Revenue Next 5Y-15.47%
EBIT growth 1Y10.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.82%
EBIT Next 3Y24.48%
EBIT Next 5Y19.25%
FCF growth 1Y-89.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.15%
OCF growth 3YN/A
OCF growth 5YN/A
STANDARD BIOTOOLS INC / LAB FAQ
What is the ChartMill fundamental rating of STANDARD BIOTOOLS INC (LAB) stock?
ChartMill assigns a fundamental rating of 2 / 10 to LAB.
What is the valuation status for LAB stock?
ChartMill assigns a valuation rating of 0 / 10 to STANDARD BIOTOOLS INC (LAB). This can be considered as Overvalued.
Can you provide the profitability details for STANDARD BIOTOOLS INC?
STANDARD BIOTOOLS INC (LAB) has a profitability rating of 0 / 10.
What is the earnings growth outlook for STANDARD BIOTOOLS INC?
The Earnings per Share (EPS) of STANDARD BIOTOOLS INC (LAB) is expected to grow by 59.6% in the next year.